Skip to main content
VCbacked
Log inGet Started

Kyverna Therapeutics

Berkeley, United States

Kyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases.

$60.0M raised
Aug 2023
Series B
BiotechnologyLife ScienceTherapeutics

Top Investors

Insight PartnersRTW InvestmentsGilead SciencesVida VenturesIntellia Therapeutics

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Kyverna Therapeutics

How much funding has Kyverna Therapeutics raised?
Kyverna Therapeutics has raised $60.0M in total funding. The most recent round was Series B. The last funding was announced in August 2023.
Who are Kyverna Therapeutics's investors?
Kyverna Therapeutics's investors include Insight Partners, RTW Investments, Gilead Sciences, Vida Ventures, Intellia Therapeutics.
Where is Kyverna Therapeutics headquartered?
Kyverna Therapeutics is headquartered in Berkeley, United States.
What does Kyverna Therapeutics do?
Kyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases.
What stage is Kyverna Therapeutics at?
Kyverna Therapeutics is at the Series B stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Kyverna Therapeutics — Funding & Investors." VCBacked, August 3, 2023, https://www.vcbacked.co/company/kyverna-therapeutics. Accessed June 10, 2026.
APA
VCBacked. (2023). Kyverna Therapeutics — Funding & Investors. Retrieved June 10, 2026, from https://www.vcbacked.co/company/kyverna-therapeutics
Wikipedia (cite web)
{{cite web |title=Kyverna Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/kyverna-therapeutics |website=VCBacked |access-date=June 10, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Virtuoso Surgical
Nashville
Pharvaris
Zug
Odyssey Therapeutics
Boston$213.0M
Tempus
Chicago
Anagram Therapeutics
Boston
Prenetics
Hong Kong